D-NMAPPD (Synonyms: (1R,2R)-B13,CAY10466) |
رقم الكتالوجGC13884
One-Click Copy Product Info
|
D-NMAPPD ((1R ، 2R) -B13) هو مثبط حمض سيراميداز
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 35922-06-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
D-NMAPPD is potent inhibitor of the acid ceramidase inhibitor.
Acid ceramidase is the lipid hydrolase responsible for the degradation of ceramide into sphingosine and free fatty acids within lysosomes. Aberrant AC activity has been observed in several human cancers and Alzheimer's disease. Overexpression of AC may prevent insulin resistant (Type II) diabetes induced by free fatty acids [2].
In vitro: D-NMAPPD was a potent inhibitor of acid ceramidase with an IC50 of ～10 μmol/l. D-NMAPPD (500 μmol/l) reduced the alkaline ceramidase activity. Treatment of melanoma cells with D-NMAPPD elevated endogenous ceramide levels in all melanoma cell populations. In HaCaT keratinocytes and A375 melanoma cells, D-NMAPPD triggered Bcl-2 overexpression abolished apoptosis. High concentrations of D-NMAPPD showed significant cytotoxic effects on HaCaT and melanoma cells. In melanoma cell lines A375, M186, Mel2A, M221, treatment of with 25 μM D-NMAPPD for 24 h resulted in a strong accumulation of ceramide. D-NMAPPD inhibited cell proliferation in a concentration-dependent manner in HaCaT keratinocytes with an IC50 of ～7 μM. D-NMAPPD exhibited no antiproliferative effect on ceramide-resistant melanoma cells.
References:
[1] Raisova M, Goltz G, Bektas M, et al. Bcl‐2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes[J]. FEBS letters, 2002, 516(1-3): 47-52.
[2] Park J H, Schuchman E H. Acid ceramidase and human disease[J]. Biochimica et Biophysica Acta (BBA)-Biomembranes, 2006, 1758(12): 2133-2138.
| Cas No. | 35922-06-6 | SDF | |
| المرادفات | (1R,2R)-B13,CAY10466 | ||
| Chemical Name | N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]-tetradecanamide | ||
| Canonical SMILES | OC[C@@H](N([H])C(CCCCCCCCCCCCC)=O)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 | ||
| Formula | C23H38N2O5 | M.Wt | 422.6 |
| الذوبان | ≤20mg/ml in ethanol;10mg/ml in DMSO;10mg/ml in dimethyl formamide | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3663 mL | 11.8315 mL | 23.663 mL |
| 5 mM | 473.3 μL | 2.3663 mL | 4.7326 mL |
| 10 mM | 236.6 μL | 1.1832 mL | 2.3663 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)